Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-09-11
2004-07-06
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S177000, C514S178000
Reexamination Certificate
active
06759400
ABSTRACT:
FIELD OF THIS INVENTION
The present invention relates to pharmacologically active compounds and to their use as medicaments. More particularly it has been found that the sterol derivatives described herein can be used for regulating meiosis.
BACKGROUND OF THIS INVENTION
In L. F. Fieser & M. Fieser: Steroids; Reinhold Publishing Corporation, 1967, 5&agr;-bromocholest-ane-3&bgr;,6&bgr;-diol; 7&agr;-bromocholestane-3&bgr;,6&agr;-diol; 7&agr;-bromocholestane-3&bgr;,6&bgr;-diol; 7&agr;-bromocholestane-3&bgr;,5&agr;-diol-6-one; 7&bgr;-bromocholestane-3&bgr;,5&agr;-diol-6-one; 3&bgr;-bromocholestane-2&agr;-ol; 5&agr;-chlorocholestane-3&bgr;,6&agr;-diol; 5&agr;-chlorocholestane-3&bgr;,6&bgr;-diol; 6&bgr;-chlorocholestane-3&bgr;,-5&agr;-diol; &Dgr;
7,9(11)
-cholestadiene-3&bgr;,6&agr;-diol; &Dgr;
7,9(11)
-cholestadiene-3&bgr;,6&bgr;-diol; cholestane-2&agr;,3&agr;-diol; cholestane-2&agr;,3&bgr;-diol; cholestane-2&bgr;,3&agr;-diol; cholestane-2&bgr;,3&bgr;-diol; cholestane-3&agr;,4&agr;-diol; cholestane-3&agr;,4&bgr;-diol; cholestane-3&bgr;,4&bgr;-diol; cholestane-3&agr;,5&agr;-diol; cholestane-3&bgr;,5&agr;-diol; cholestane-3&bgr;,6&agr;-diol; cholestane-3&bgr;,6&bgr;-diol; cholestane-3&bgr;,22&agr;-diol; cholestane-3&bgr;,22&bgr;-diol; cholestane-3&bgr;,7&agr;,8&agr;-triol; &Dgr;
5
-cholestane-3&bgr;,4&agr;-diol; &Dgr;
5
-cholestane-3&bgr;,4&bgr;-diol; &Dgr;
5
-cholestane-3&bgr;,22&agr;-diol; &Dgr;
5
-cholestane-3&bgr;,24&bgr;-diol; &Dgr;
5
-cholestane-3&bgr;,22&bgr;-diol; &Dgr;
5
-cholestane-3&bgr;,24&agr;-diol; &Dgr;
5
-cholestene-30,24&bgr;-diol; &Dgr;
6
-cholestene-&Dgr;
8(14)
-cholestene-3&bgr;,9&agr;-diol; &Dgr;
11
-cholestene-3&agr;,24-diol; &Dgr;
5
-cholestene-3&bgr;,6-diol-7-one; &Dgr;
5
-cholestene-4&agr;-ol-3-one; &Dgr;
5
-cholestene-3&bgr;,4&bgr;,7&agr;-triol; coprostane-3&agr;,5&bgr;-diol; coprostane-3&bgr;,5&bgr;-diol; coprostane-3&bgr;,6&bgr;-diol; coprostane-4&bgr;,5&bgr;-diol-3-one and 20&bgr;-hydroxy-20-isocholesterol are mentioned in the subject index.
In German patent application having publication no. 1,183,079, a process for preparing 4&agr;-hydroxy-5&agr;-cholestan-3-one is mentioned in Example 5. This compound is not stated to have any utility other than as an intermediate.
In German patent application having publication no. 1,224,738, cholestan-3&bgr;,5&agr;,6&bgr;-triol-3&bgr;-hemisuccinate; cholestan-3&bgr;,5&agr;,6&bgr;-triol-3&bgr;-hemisuccinate-6&bgr;-acetate; cholestan-3&bgr;,5&agr;,6&bgr;-triol-3&bgr;-hemisuccinate-6&bgr;-formiate; cholestan-3&bgr;,5&agr;,6&bgr;-triol-3&bgr;-sulphate and cholestan-3&bgr;,5&agr;,6&bgr;-triol-3&bgr;-phosphate are mentioned in Examples 1-5, respectively. It is mentioned that the compounds described therein can be used for the treatment of arteriosclerosis.
In German patent application having publication no. 2,201,991 C2, a process for the preparation of insecticides such as 2&bgr;,3&bgr;,14&agr;,22(R),25-pentahydroxycholest-7-en-6-one is described.
German patent application having publication no. 2,236,778 B2 relates to a novel insecticide, i.e., cholest-7-en-2&bgr;,3&bgr;,5&bgr;,11&bgr;,14&agr;,20(R),22(R)-heptahydroxy-6-one.
In German patent application having publication no. 2,409,971 B2, 5,24-cholestadien-3&bgr;ol; 5-cholesten-3&bgr;,24,25-triol-3&bgr;-acetate; 5-cholesten-3&bgr;,24,25-triol-3&bgr;,24-diacetate; 5,25-cholestadien-3&bgr;-ol acetate; 5-cholesten-3&bgr;,25,26-triol-3&bgr;-acetate and 5-cholesten-3&bgr;,25,26-triol are mentioned in Examples 1, 1, 2, 3, 3 and 6, respectively. It is mentioned that the compounds described therein are valuable intermediates for the technical preparation of 24,25(or 25,26)-dihydroxycholecalciferol.
In German patent application having publication no. 2,453,648 B2, cholest-5&agr;-an-3&bgr;,6&agr;-diol; cholest-5&bgr;-an-3&bgr;,6&bgr;-diol; cholest-5&agr;-an-3,6-dione; cholest-5&agr;-an-6&bgr;-ol-3-one and cholest-5&agr;-an-2&agr;-bromo-6&bgr;-ol-3-one are mentioned as intermediates in column 6.
In German patent application having publication no. 2,415,676, cholestan-30&bgr;,25-diol-3&bgr;-acetate; cholestan-3&bgr;,5&agr;,25-triol-3&bgr;-acetate; cholestan-3&bgr;,5&agr;,25-triol; cholestan-5&agr;,25-diol-3-one; cholest-4-en-25-ol-3-one and cholesta-4,6-dien-25-ol-3-one are mentioned as compounds III, IV, X, XI XII and XIII, respectively. It is suggested that the compounds described therein may be substantially stronger that vitamin D
3
.
In German patent application having publication no. 2,546,715 A1, a process for preparing 1&agr;,3&bgr;-dihydroxycholest-5-en and 1&agr;,3&bgr;-dihydroxycholest-6-en is mentioned in Example 1 (compounds V and II). It is suggested that the compounds described therein are useful additives to foodstuff and can be used in vitamin compositions.
In German patent application having publication no. 2,822,486 A1,3&agr;,6&agr;-dihydroxy-5&bgr;-cholestan-24-one; 3&agr;,6&agr;,24-trihydroxy-5&bgr;-cholestan; 3-chlorocholest-5,24-dien; 3&bgr;-hydroxycholest-5-en-24-on acetate and 3-chlorocholest-5-en-24-on are mentioned in Example 3, 4, 5a and 6c and as formula VII, respectively. It is mentioned that the compounds described therein can be used as intermediates for the preparation of desmosterin, derivatives thereof and other active vitamin D.
In German patent application having publication no. 3,241,172 A1, cholestan-25-fluoro-3&bgr;,22(S)-diol; cholestan-25-chloro-3&bgr;,22(S)-diol; cholestan-25-methyl-3&bgr;,22-diol; cholestan-25-methyl-3&bgr;,22-diol-3-hydrogenbutandioate and cholestan-25-methyl-3&bgr;,22-diol-bis-hydrogenbutandioate are mentioned in claims 2, 3, 5, 6 and 7, respectively. It is mentioned that the compounds described therein inhibit the activity of HMGCOA reductase and the formation of blood cholesterol.
In German patent application having publication no. 3,390,016 C2, a process for preparing 1&agr;,25-dihydroxy-26,26,26,27,27,27-hexafluorocholes-5-en is described. It is mentioned that this compound can easily be converted into a compound having vitamin D
3
like activity.
In Danish patent application having publication no. 123,767, a process for preparing 2&bgr;,3&bgr;,14&agr;,22,25-pentahydroxy-&Dgr;
7
-5&bgr;-cholesten-6-one is mentioned. It is mentioned that the compounds described therein have an action on the central nervous system.
In European patent application having publication no. 15,122 B1, 25-hydroxy-3&bgr;-[(tetrahydro-2H-pyran-2-yl)oxy]cholest-5-en-24-on; 3&bgr;-[(tetrahydro-2H-pyran-2-yl)oxy]cholest-5-en-24-on; 25-hydroxy-24-oxocholesterol-3&bgr;-acetate; 24-oxocholesterol-3&bgr;-acetate; 25-hydroxy-24-oxocholesterol; 24,25-dihydroxycholesterol; 3&agr;,6&agr;,25-trihydroxy-24-oxo-5,&bgr;-cholestane; 1&agr;,25-dihydroxy-24-oxocholesterol; 1&agr;,24,25-trihydroxycholesterol; 3&bgr;-hydroxy-24-oxo-cholesta-5,7-dien; 3&bgr;,25-dihydroxy-24-oxocholesta-5,7-dien; 3&bgr;-hydroxy-24-oxocholesta-5,7-dien; 1&agr;,3&bgr;-dihydroxy-24-oxocholesta-5,7-dien and 1&agr;,3&bgr;,25-trihydroxy-24-oxocholesta-5,7-dien are mentioned in Examples 1, 1, 4, 4, 5ii, 5(1), 6i, 7, 7(2), 8iii, 8iv, 8iv, 9iii and 9iv respectively. It is mentioned that the compounds described therein are useful intermediates convertible into active vitamin D
3
.
In European patent application having publication ,no. 63,678 B1 (24R)-3&bgr;,24,25-trihydroxycholest-5-en; (24RS)-3&bgr;,24,25-trihydroxycholest-5-en and (24R)-1&bgr;,3&bgr;,24,25-tetrahydroxycholest-5-en are mentioned in Examples 1e, 3e and 4f, respectively. It is mentioned that the compounds described therein can be used as intermediates in the preparation of vitamin D
3
derivatives.
In European patent application having publication no. 322,036 A1, 4,4-dimethyl-24-methylene-3&bgr;-sulphooxy-12&agr;-acetoxycholesta-8,14-dien-2&agr;,11&bgr;-diol; 4,4-dimethyl-24-methylene-3&bgr;-sulphooxy-12&agr;-acetoxycholest-8-en-2&agr;,11&bgr;-diol; 4,4-dimethyl-24-methylene-12&agr;-acetoxycholesta-8,14-dien-2&agr;,3&bgr;,11&bgr;-triol; 4,4-dimethyl-24-methylene-12&agr;-acetoxy-cholesta-8,14-dien-3&bgr;,11&bgr;-diol; 4,4-dimethyl-24-methylene-12&agr;-acetoxycholest-8-en-2&agr;,3&bgr;,11&bgr;-triol; 4,4-dim
Faarup Peter
Grondahl Christian
Gronvald Frederik Christian
Murray Anthony
Ottesen Jan Lund
Badio Barbara P.
Green Reza
Novo Nordisk A S
Smith Len S.
LandOfFree
Meiosis regulating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Meiosis regulating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Meiosis regulating compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3191583